Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Trades near a two-decade low as temporary headwinds, including contract pricing lags, fluid conservation following Hurricane Helene, and a pause on its Novum IQ platform, mask the earnings power of its core medtech franchise.
— Richard Pzena
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Baxter International Inc.
Baxter sought to amend its certificate of incorporation regarding board size, which would have given the board authority to increase the number of directors up to a cap of 17. Academic literature supports...
We initiated a position in Baxter during the quarter in the high teens.